Author: Ravi Shankar

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Dividend & Income Trust (NYSE:GDV) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.15 per share for each of January, February, and March 2027.

The Board of Trustees increased the annual distribution 7% to $1.80 per share, which will be paid $0.15 per share monthly, commencing with the January 2026 monthly distribution.

Distribution Month	Record Date	Payable Date		Distribution Per Share
January	January 14, 2027	January 22, 2027		$0.15
February	February 11, 2027	February 19, 2027		$0.15
March	March 17, 2027	March 24, 2027		$0.15

Additionally, the Board of Trustees continues to evaluate potential strategic opportunities for the Fund in what we believe to be an attractive environment to invest in the broader equity markets.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2026 would include approximately 8% from net investment income and 92% from net capital gains on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

Carter Austin
(914) 921-5475

About The Gabelli Dividend & Income Trust
The Gabelli Dividend & Income Trust is a diversified, closed-end management investment company with $3.4 billion in total net assets whose primary investment objective is to provide a high level of total return with an emphasis on dividends and income. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE – GDV
CUSIP – 36242H104

Investor Relations Contact:
Carter Austin
(914) 921-5475
caustin@gabelli.com

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Global Small and Mid Cap Value Trust (NYSE:GGZ) (the “Fund”) declared a $0.21 per share cash distribution payable on December 18, 2026 to common shareholders of record on December 11, 2026.

The Fund intends to pay a quarterly distribution of an amount determined each quarter by the Board of Trustees. In addition to the quarterly distributions, and in accordance with the minimum distribution requirements of the Internal Revenue Code for regulated investment companies, the Fund may pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the quarterly distributions for that year.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the current financial market environment. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2026 would include approximately 18% from net investment income and 82% from net capital gains on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the quarterly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

Bethany Uhlein
(914) 921-5546

About The Gabelli Global Small and Mid Cap Value Trust
The Gabelli Global Small and Mid Cap Value Trust is a diversified, closed-end management investment company with $157 million in total net assets whose primary investment objective is to achieve long-term capital growth of capital. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities (such as common stock and preferred stock) of companies with small or medium sized market capitalizations. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

Investor Relations Contact:
Bethany Uhlein
(914) 921-5546
buhlein@gabelli.com

NYSE – GGZ
CUSIP – 36249W104

MINNEAPOLIS, Nov. 11, 2026 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB: PETV) (“PetVivo” or the “Company”), a biomedical device company focused on the commercialization of innovative medical devices and therapeutics for equine and companion animals, announced today that it plans to file its Quarterly Report on Form 10-Q for the fiscal second quarter ended September 30, 2026, on Friday, November 13, 2026.

Beginning with this filing, and continuing in subsequent quarters, the Company intends to communicate its quarterly financial results and related disclosures through its SEC filings and does not intend to issue separate quarterly results press releases or conduct quarterly earnings conference calls. As a company traded on the OTCQB^® Venture Market, PetVivo will continue to provide public access to its financial results and related disclosures through its required SEC reports. Shareholders are encouraged to review these reports through the SEC’s EDGAR database.

The Company intends to revisit this approach as its business and investor base evolve and currently anticipates resuming quarterly earnings releases and conference calls in connection with any future uplisting to a national securities exchange. Any such uplisting would be subject to applicable listing requirements and approvals.

This change in communication format does not change PetVivo’s commitment to keeping shareholders informed and maintaining an open dialogue. The Company welcomes questions, feedback, and requests for discussion following review of its reports. Management remains available to discuss PetVivo’s publicly disclosed results, business activities, and strategic priorities.

Shareholders may contact investors@petvivo.com or call the Company’s main office at (952) 405-6216 to submit questions or request a conversation with the appropriate member of the management team.

PetVivo appreciates its shareholders’ continued interest and support.

For more information about PetVivo Holdings, Inc. and its innovative products please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQB: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG^® with OsteoCushion^® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of GAMCO Global Gold, Natural Resources & Income Trust (NYSE American: GGN) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions. The Board of Trustees declared cash distributions of $0.035 per share for each of January, February, and March 2027. Based on current dynamics, the Fund may make distributions in excess of the Fund’s distributable earnings. It is currently expected that distributions to common shareholders in 2026 will primarily constitute a return of capital for tax purposes.

The Board of Trustees increased the annual distribution 16% to $0.42 per share, which will be paid $0.035 per share monthly, commencing with the October 2026 monthly distribution.

Distribution Month	Record Date	Payable Date	Distribution Per Share
January	January 14, 2027	January 22, 2027	$0.035
February	February 11, 2027	February 19, 2027	$0.035
March	March 17, 2027	March 24, 2027	$0.035

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

Because the Fund’s current monthly distributions are subject to modification by the Board of Trustees at any time and the Fund’s income will fluctuate, there can be no assurance that the Fund will pay distributions at a particular rate or frequency. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution.

Short-term capital gains, qualified dividend income, ordinary income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. There are no capital loss carryforwards for book purposes. Therefore the Fund, on a book basis, may be distributing short term gains generated from option premiums that will not be taxable in 2027 because of the capital loss carryforwards available on a tax basis. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2027 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2027 distributions in early 2028 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

David Schachter
(914) 921-5057

The Fund’s NAV per share will fluctuate with changes in the market value of the Fund’s portfolio securities. Stocks are subject to market, economic, and business risks that cause their prices to fluctuate. Investors acquire shares of the Fund on a securities exchange at market value, which fluctuates according to the dynamics of supply and demand. When Fund shares are sold, they may be worth more or less than their original cost. Consequently, you can lose money by investing in the Fund.

Covered Call and Other Option Transaction Risks. There are several risks associated with writing covered calls and entering into other types of option transactions. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, resulting in a given transaction not achieving its objectives. In addition, a decision as to whether, when, and how to use covered call options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful because of market behavior or unexpected events. As a writer of a covered call option, the Fund forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the exercise price of the call option, but has retained the risk of loss should the price of the underlying security decline.

About The GAMCO Global Gold, Natural Resources & Income Trust
The GAMCO Global Gold, Natural Resources & Income Trust is a non-diversified, closed-end management investment company with $1.0 billion in total net assets whose primary investment objective is to provide a high level of current income. The Fund invests primarily in equity securities of gold and natural resources companies and intends to earn income primarily through a strategy of writing (selling) primarily covered call options on equity securities in its portfolio. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE American – GGN
CUSIP – 36465A109

Investor Relations Contact: 
David Schachter
(914) 921-5057
dschachter@gabelli.com

ANNOUNCEMENT NO. 328
11 November 2026

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 6 November 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec A/S to 15.02%, thereby exceeding the 15% threshold pursuant to section 38 of the Danish Capital Markets Act.

BlackRock, Inc.’s position at that time was as follows:

• Voting rights attached to shares: 15.02%
• Voting rights through financial instruments: 0.22%
• The total of both: 15.24%

Additional Information
Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

• Major shareholder announcement – BlackRock, Inc

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE:GNT) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions. The Board of Trustees declared cash distributions of $0.06 per share for each of January, February, and March 2027. Based on current dynamics, the Fund may make distributions in excess of the Fund’s distributable earnings. It is currently expected that distributions to common shareholders in 2026 will primarily constitute a return of capital for tax purposes.

Distribution Month	Record Date	Payable Date	Distribution Per Share
January	January 14, 2027	January 22, 2027	$0.06
February	February 11, 2027	February 19, 2027	$0.06
March	March 17, 2027	March 24, 2027	$0.06

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

Because the Fund’s current monthly distributions are subject to modification by the Board of Trustees at any time and the Fund’s income will fluctuate, there can be no assurance that the Fund will pay distributions at a particular rate or frequency. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution.

Short-term capital gains, qualified dividend income, ordinary income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. There are no capital loss carryforwards for book purposes. Therefore the Fund, on a book basis, may be distributing short term gains generated from option premiums that will not be taxable in 2027 because of the capital loss carryforwards available on a tax basis. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2027 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2027 distributions in early 2028 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

David Schachter
(914) 921-5057

The Fund’s NAV per share will fluctuate with changes in the market value of the Fund’s portfolio securities. Stocks are subject to market, economic, and business risks that cause their prices to fluctuate. Investors acquire shares of the Fund on a securities exchange at market value, which fluctuates according to the dynamics of supply and demand. When Fund shares are sold, they may be worth more or less than their original cost. Consequently, you can lose money by investing in the Fund.

Covered Call and Other Option Transaction Risks. There are several risks associated with writing covered calls and entering into other types of option transactions. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, resulting in a given transaction not achieving its objectives. In addition, a decision as to whether, when, and how to use covered call options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful because of market behavior or unexpected events. As the writer of a covered call option, the Fund forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the exercise price of the call option, but has retained the risk of loss should the price of the underlying security decline.

About The GAMCO Natural Resources, Gold & Income Trust
The GAMCO Natural Resources, Gold & Income Trust is a diversified, closed-end management investment company with $175 million in total net assets whose primary investment objective is to provide a high level of current income. The Fund invests primarily in equity securities of gold and natural resources companies and intends to earn income primarily through a strategy of writing (selling) primarily covered call options on equity securities in its portfolio. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE – GNT
CUSIP – 36465E101

Investor Relations Contact:
David Schachter
(914) 921-5057 dschachter@gabelli.com

Reaffirms Annualized Distribution of $1.32 Per Share

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Global Utility & Income Trust (NYSE American: GLU) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.11 per share for each of January, February, and March 2027.

The Board of Trustees increased the annual distribution 10% to $1.32 per share, which will be paid $0.11 per share monthly, commencing with the January 2026 monthly distribution.

Distribution Month	Record Date	Payable Date	Distribution Per Share
January	January 14, 2027	January 22, 2027	$0.11
February	February 11, 2027	February 19, 2027	$0.11
March	March 17, 2027	March 24, 2027	$0.11

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2026 would include approximately 21% from net investment income and 79% from net capital gains on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

Adam Tokar
(914) 457-1079

About The Gabelli Global Utility & Income Trust
The Gabelli Global Utility & Income Trust is a diversified, closed-end management investment company with $142 million in total net assets whose primary investment objective is to seek a consistent level of after-tax total return for its investors with an emphasis on tax-advantaged dividend income under current tax law. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE American – GLU
CUSIP – 36242L105

Investor Relations Contact:
Adam Tokar
(914) 457-1079
atokar@gabelli.com

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Healthcare & Wellness^Rx Trust (NYSE: GRX) (the “Fund”) approved an increase in the annualized distribution to $0.80 per share, which will be paid $0.20 per share quarterly, commencing with the quarterly distribution payable on December 18, 2026 to common shareholders of record on December 11, 2026.

The Fund intends to pay a quarterly distribution determined by the Board of Trustees. In addition to the quarterly distributions, and in accordance with the minimum distribution requirements of the Internal Revenue Code for regulated investment companies, the Fund may pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the quarterly distributions for that year.

Each quarter, the Board of Trustees reviews the amount of any potential distribution and the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the current financial market environment. The Fund’s distribution policy is subject to modification or termination by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject up to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2026 would include approximately 11% from net investment income, 52% from net capital gains and 37% would be deemed a return of capital on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the quarterly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

Bethany Uhlein
(914) 921-5546

About The Gabelli Healthcare & Wellness^Rx Trust

The Gabelli Healthcare & Wellness^Rx Trust is a diversified, closed-end management investment company with $237 million in total net assets whose primary investment objective is long-term growth of capital. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE: GRX
CUSIP – 36246K103

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
Investor Relations Contact:
Bethany Uhlein
914.921.5546
buhlein@gabelli.com

RYE, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of The GDL Fund (NYSE:GDL) (the “Fund”) declared a $0.12 per share cash distribution payable on December 18, 2026 to common shareholders of record on December 11, 2026.

The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment.  The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

The Fund makes annual distributions of its realized net long-term capital gains and quarterly cash distributions of all or a portion of its investment company taxable income to common shareholders.  A portion of the distribution may be a return of capital and various factors will affect the level of the Fund’s income, such as its asset mix and use of merger arbitrage strategies.  To permit the Fund to maintain more stable distributions, the Fund may distribute more than the entire amount of income earned in a particular period.  Because the Fund’s current quarterly distributions are subject to modification by the Board of Trustees at any time and the Fund’s income will fluctuate, there can be no assurance that the Fund will pay distributions at a particular rate or frequency.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital.  Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Short-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year.  Long-term capital gains, if any, are distributed in the final distribution of the year.  Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2026 would include approximately 10% from net investment income, 75% from net capital gains and 15% would be deemed a return of capital on a book basis.  This does not represent information for tax reporting purposes.  The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com).  The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the quarterly estimates.  Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution.  All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing.  For more information regarding the Fund’s distribution policy and other information about the Fund, call:

Priscilla De Vargas
(914) 921-7761

About The GDL Fund
The GDL Fund is a diversified, closed-end management investment company with $117 million in total net assets whose investment objective is to achieve absolute returns in various market conditions without excessive risk of capital.  The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE – GDL
CUSIP – 361570104

Investor Relations Contact:
Priscilla De Vargas
(914) 921-7761
pdevargas@gabelli.com

Company to assess aerospace power requirements and potential space applications for diamond betavoltaic technology

MESQUITE, Nev, Nov. 11, 2026 (GLOBE NEWSWIRE) — MESQUITE, Nev., November 11, 2026 – Nuclear Diamond Batteries, Inc. (OTCID: NDBI) (“NDBI” or the “Company”) today announced that a representative of its controlled subsidiary, AtomiQ, Inc. (“AtomiQ”), plans to attend the 2026 NASA Aerospace Battery Workshop, November 17-19, 2026, at the U.S. Space & Rocket Center in Huntsville, Alabama.

AtomiQ plans to engage with space battery engineers, aerospace contractors, and government researchers to better understand mission requirements, assess potential applications, and identify prospective research and development collaborators. These discussions are intended to help inform development priorities for specialized power systems used where sunlight is limited and battery replacement is difficult or impractical.

Hosted by NASA’s Marshall Space Flight Center, the annual NASA Aerospace Battery Workshop brings together government, industry, and academic participants to discuss battery research, testing, flight experience, and operational challenges.

AtomiQ’s planned role is as an attendee. The Company has no agreement with NASA, and attendance does not constitute a NASA evaluation, partnership, or endorsement of the Company or its technology.

Potential Space Applications

Betavoltaic devices convert energy from radioactive decay directly into low levels of electricity within a semiconductor, without relying on sunlight or recharging the power source. Their potential operating life depends on the isotope, device design, and operating conditions. Diamond is a candidate semiconductor material because of its radiation tolerance and thermal properties.

Potential applications include low-power sensors, clocks, memory retention, and wake-up circuits aboard small satellites or lunar instruments. With suitable power management, compatible rechargeable storage devices could accumulate energy for intermittent operations. These applications would complement solar arrays, conventional batteries, and larger radioisotope power systems.

AtomiQ’s technology remains pre-commercial and has not been qualified for spaceflight. Potential applications remain subject to engineering, performance testing, regulatory requirements, and mission-specific qualification; operating life, power output, and environmental tolerance must be established for each design.

AtomiQ Patent Portfolio

AtomiQ’s portfolio includes U.S. Patent No. 12,394,534 B2 for nuclear-voltaic power-source architecture and U.S. Patent No. 12,759,882 B2 for producing and modifying carbon nano-onion materials. Together, these patents address electricity generation and advanced materials potentially relevant to energy storage.

The Company also previously announced a USPTO Notice of Allowance covering 19 claims in U.S. Patent Application No. 17/928,967, concerning a high-porosity metal-organic framework electrode incorporating carbon nano-onion materials. A notice of allowance is distinct from an issued patent.

About Nuclear Diamond Batteries

Nuclear Diamond Batteries, Inc. (OTCID: NDBI), through its controlled subsidiary AtomiQ, Inc., focuses on developing nuclear diamond battery technologies and advanced materials for applications requiring extended operating life, reliability, and reduced maintenance. Potential markets include aerospace, defense, industrial sensors, medical technologies, and remote infrastructure. The Company intends to pursue commercialization through research and development, technology licensing, and strategic partnerships.

Forward Looking Statements

This release contains forward-looking statements regarding planned attendance and discussions, development priorities, potential applications, patent protection, and commercialization. These statements reflect management’s current expectations and are not guarantees. Actual results may differ materially because of funding needs, technical feasibility, performance and reliability, testing and space qualification, isotope availability, manufacturing, regulatory requirements, and patent protection.

Attendance or discussions may not lead to contracts, funding, testing programs, partnerships, or other commercial results. Allowed patent applications may not issue, and issued patents may not provide meaningful protection. The Company needs additional capital, and there is substantial doubt about its ability to continue as a going concern without it. Additional risks are described in the Company’s public disclosures available through OTC Markets. The Company undertakes no obligation to update forward-looking statements, except as required by law.

Media and Investor Contact

Nuclear Diamond Batteries, Inc.
info@nucleardiamondbatteriesinc.com
https://nucleardiamondbatteriesinc.com/
https://x.com/NDBI_stock